The UK GLP-1 Grey Market: 135 Companies, 1 Death, and Why the Safe Path Matters
We audited every UK company with 'peptide' in its name on Companies House. 98 are brand new with no track record, none of the credible ones supply GLP-1, and one woman has already died. Here's what patients need to know — and the safe alternative.
In May 2025, a 53-year-old woman in the UK died after receiving illicit semaglutide injections at a beauty salon. Her two daughters went public to warn other women. Five months later, the MHRA dismantled an illegal manufacturing facility in Northampton, seizing more than 2,000 pre-filled pens of tirzepatide and retatrutide — the latter a drug still in clinical trials and not legally available anywhere in the world. As of January 2025, 82 deaths had been reported to the MHRA's Yellow Card scheme in connection with GLP-1 medicines.
These are not isolated incidents. They are the visible tip of a market that has exploded in the United Kingdom over the last twelve months — a grey market in research-grade peptides, sold to consumers under "research only" disclaimers, sourced largely from China, and operated by companies that did not exist a year ago.
We mapped this market. The findings should change how every UK patient thinks about where their GLP-1 medicine comes from.
What we did
We pulled the full Companies House register for every company with "peptide" or "peptides" in its name. We classified each one by status, age, and whether it had filed accounts. We then checked the websites and product catalogues of every credible supplier, and cross-referenced the regulatory record. The result is the most complete picture available of the UK peptide industry as it stands today.
Here is what the data shows.
Finding 1: The peptide gold rush is real, and it is brand new
There are 135 companies on the UK register with "peptide" or "peptides" in their name. Of these:
That sounds like a substantial industry. It is not. Of those 106 active companies, only 8 are old enough (more than 21 months since incorporation) to have hit their first statutory accounts deadline. The other 98 — that is 92% of the active register — were incorporated within the last twelve months.
Almost 80 of them were incorporated in the last six months alone. Two were incorporated on the day we ran this audit, 29 April 2026. None of the 98 has ever filed a set of accounts. None has any verifiable trading history. None has been audited by HMRC. None has demonstrated a manufacturing capability, a quality-control infrastructure, a banking relationship that survived more than a season, or anything else that would normally indicate a real business.
This is what a gold rush looks like in Companies House data — a flood of cheap shell registrations chasing a sudden consumer-demand wave.
Finding 2: Of the eight companies old enough to have a track record, exactly zero supply GLP-1
We checked the websites and product catalogues of every one of the eight filing-eligible companies. The results are striking:
| Company | Founded | Sells GLP-1? |
|---|---|---|
| Peptide Protein Research Ltd | 1999 | No GLP-1 catalogue product |
| Cambridge Peptides Ltd | 2004 | Explicitly refuses |
| Cupid Peptide Company Ltd | 2012 | No (cell-permeable peptide research tools) |
| Peptide Groove LLP | 2013 | Unclear |
| Origin Peptides Ltd | 2018 | Indirect mention, no product |
| Peptide Pets Ltd | 2022 | No |
| Triple Helical Peptides Ltd | 2023 | No (collagen-mimetic research) |
| Taiwan Oyi Peptide Co Ltd | 2023 | Dormant company |
The most telling case is Cambridge Peptides Ltd, the closest thing the UK has to an established peptide synthesis house. Their website carries a clear disclaimer: *"Our peptides are strictly for scientific research and industrial applications. We do not supply peptides for personal use, including bodybuilding, weight loss, skincare etc."*
The credible UK peptide industry has firewalled itself out of the GLP-1 / weight-loss market. They will not touch it. The 98 newly registered shell companies are filling that void.
Finding 3: Where the drugs actually come from
A peer-reviewed paper in *Emerging Trends in Drugs, Addictions, and Health* (2024) — "Made in China: The international supply of illicit Semaglutide and weight-loss medicines online" — laid out the supply chain in detail. Independent investigations by the National Association of Boards of Pharmacy in the United States and Partnership for Safe Medicines confirmed the same picture. The grey-market funnel works like this:
Despite the disclaimers, the consumer intent is unambiguous. We checked one popular UK research-peptide retailer that organises its inventory under category headings such as "Fat Loss," "Muscle Growth," and "Anti-Aging." Tirzepatide vials retail at around £43; retatrutide at around £60. By comparison, a month of branded Wegovy on UK private prescription is £150–£250. The grey market exists because the legal market has priced itself out of reach for most people who want access.
Finding 4: There is no easy way for a consumer to verify what is in the vial
We thought hard about whether a customer can protect themselves with a home test. The honest answer is: not really.
Peptides like semaglutide and tirzepatide are 30–40 amino acid molecules with unusual modifications. Telling them apart from other peptides — or from saline — requires mass spectrometry or high-performance liquid chromatography. These are laboratory techniques that cost £50–£200 per sample at a third-party lab and take 1–2 weeks for results. Consumer-grade lateral-flow tests of the kind that exist for pregnancy or COVID do not exist for sema/tirz/reta. The reagents and antibodies needed to make one are available in research labs, but no one has commercialised a consumer in-vitro diagnostic.
What a consumer can do at home — visual inspection, a pH strip, a microscope photo to compare consistency, a symptom log, or continuous glucose monitoring as a downstream proxy — catches gross failures only. A vial that contains saline instead of semaglutide can sometimes be spotted. A vial that contains 67% of the labelled dose, or a near-relative peptide that the manufacturer substituted, will look identical to the real product.
This matters because the actual harms in this market come from exactly those subtle failures.
Finding 5: Documented harm is no longer hypothetical
The case literature on grey-market GLP-1 use is now substantial enough to draw a clear pattern. Four distinct failure modes have caused documented hospitalisations and deaths.
Massive dose errors from reconstitution. Grey-market vials are sold in raw milligrams of API. The user must reconstitute the powder with bacteriostatic water, draw the correct volume into an insulin syringe, and inject. The maths is unforgiving. A published case series of semaglutide dosing errors on initiation includes a 53-year-old man who injected 2 mg instead of 0.1 mg — a 20-fold overdose — and was hospitalised, and a 45-year-old woman who injected 2.4 mg instead of 0.25 mg. Neither case report ties the error to a grey-market source specifically, but both illustrate how unforgiving the reconstitution maths is for anyone drawing a dose from raw milligrams rather than a pre-filled, pre-dosed pen.
Counterfeit content. Three counterfeit batches of branded Ozempic passed through the regulated global supply chain in late 2023, identified by Novo Nordisk and national regulators — Brazil and the UK in October, the US in December. In the UK, the MHRA found 369 fake pens at two wholesalers before any reached a patient. Some counterfeit batches contained insulin instead of semaglutide, leading to severe hypoglycaemia. The FDA's adverse-event reporting system has logged 42 reports of counterfeit semaglutide, 28 classified "serious," with outcomes including deaths.
Sterility failures. Non-sterile manufacturing causes injection-site abscesses, bacteraemia, and sepsis. The Northampton raid suggested a level of sanitation in domestic UK clandestine manufacturing that no one would tolerate in a regulated pharmacy.
No medical screening. Even a perfectly genuine, perfectly dosed vial of semaglutide is dangerous in the wrong patient. It is contraindicated in family history of medullary thyroid carcinoma, severe gastroparesis, gallbladder disease, and pregnancy. Drug interactions with oral contraceptives reduce contraceptive efficacy. The MHRA's own Drug Safety Update has flagged misuse risk repeatedly. None of these checks happen when a patient orders a £43 vial off a Shopify store.
The real-world impact in the UK alone, in 2025: a beauty-salon death, the Northampton manufacturing raid, an MHRA investigation into peptide clinics for unlawful health claims, and a Yellow Card system actively recruiting hospitalised pancreatitis cases.
Why this market exists
It is worth being honest about the demand side. The UK has no compounding pharmacy infrastructure of the kind that exists in the United States under FDA 503A and 503B regulations. Branded GLP-1s on private prescription cost £150–£250 per month. NHS prescribing is restricted by BMI thresholds and multi-month waitlists. Consumers who fall outside the eligibility window — or who simply cannot wait — face a binary choice: pay private clinic prices that compound to thousands of pounds a year, or buy off the grey market at a tenth of the cost.
The grey market exists because the legal market does not serve them. That demand is not going to disappear. The MHRA crackdown will reduce supply, but it will also push the market further underground and further beyond any consumer's ability to verify what they are receiving.
The safe path
Magistra does not match patients with doctors or sell medication — we are a data platform. What we offer is the evidence you take *to* a licensed doctor or pharmacist, not a substitute for one. That's built on two things:
1. An independent, fully-sourced GLP-1 outcomes database, powering personalised predictions. Magistra maintains a GLP-1 safety and efficacy database in which every data point is traceable to a citable source — drawn from PubMed, FDA FAERS, ClinicalTrials.gov, regulatory reports across multiple jurisdictions, and patient-contributed real-world experiences. We use it to give every visitor a personalised forecast of their likely weight trajectory, side-effect risk, muscle-preservation profile, and discontinuation outcomes — evidence to discuss with your own doctor before starting or changing treatment. The methodology is publication-grade — TRIPOD-compliant, with calibration and bias adjustments — and the underlying data is publicly available through our research API. Our models are open. Our methodology is documented.
2. Live intelligence on the global supply chain. Magistra tracks GLP-1 supply, demand, and international trade across major global markets — patent expiries, licensed generic launches, regulator-approved manufacturers, pricing across jurisdictions, supply disruptions, and emerging access pathways. This is not a sales catalogue. It is a transparent, continuously updated picture of where the legitimate global supply is and how it is changing, so you and your own doctor or pharmacist can check what's genuinely available, properly licensed, and properly cold-chain-managed for your country. Our GLP-1 Economics hub is the public-facing window into this work.
Neither of these is a substitute for seeing a licensed prescriber before starting or changing a GLP-1 medication — always go through a registered doctor or pharmacist, never the grey market. What they give you is independent evidence instead of a sales pitch, which is exactly what the grey market cannot offer.
What you should do
If you are considering GLP-1 medication for weight management, the questions that matter are simple:
Magistra is built to answer all four questions on your behalf. The grey market is built to avoid them.
See your personalised forecast
What Magistra actually offers today — we publish data, we do not prescribe, dispense, or match you with anyone:
Correction (4 September 2026): the source journal for "Made in China" was corrected to Emerging Trends in Drugs, Addictions, and Health (it was previously misattributed to a different journal, Drug Use and Misuse); the 2023 counterfeit-Ozempic paragraph was corrected to name the three countries involved (Brazil, the UK, the US) rather than describing all three batches as a UK event; and a case citation (PMID 40849680, a diabetic patient's overdose during a mental-health crisis on a legitimately prescribed pen) was removed from the reconstitution-error paragraph, which it did not support — it is not a grey-market case. Every other figure, company record, and citation on this page was checked against a primary or independently reporting source and left standing.
This article is educational and based on publicly available data from Companies House (UK), the MHRA, the FDA, the WHO, and peer-reviewed medical literature. Sources include: Companies House register (April 2026), MHRA Drug Safety Updates, the Partnership for Safe Medicines (October 2025), "Made in China: The international supply of illicit Semaglutide and weight-loss medicines online" (Emerging Trends in Drugs, Addictions, and Health, 2024), the FDA Adverse Event Reporting System, and a case report in a peer-reviewed clinical toxicology journal (PubMed PMID 38470137). Magistra does not provide medical advice. Always consult a licensed healthcare provider before starting or changing any medication.
Bekijk uw eigen cijfers
Onze gratis voorspeller schat uw bijwerkingsrisico en gewichtsverloop, met bij elk cijfer het aantal vermelde percentages en afzonderlijke bronnen. Geen account nodig.
Open de voorspellerWerkt u met de data zelf? De gedateerde momentopname achter deze cijfers is te koop als eenmalige aankoop, naast de gratis publieke API: Data & API.